Authors: Zhen Li, Aline Zaparte, Xiaoming Fu, Xinmin Li, David Wong, aaron gibson, Kiersten Gorse, Zeneng Wong, Stanley Hazen, David Lefer, Pearl Quijada, Cat Makarewich, Thomas Sharp
Published: 2024-10-09
DOI: 10.1161/res.135.suppl_1.tu043
Source: Full article
Background: Numerous gut microbial metabolites including phenylacetylglutamine (PAGln) are associated with increased cardiovascular disease risk and mortality. However, little is known about the cellular-specific perturbations by which PAGln may drive cardiovascular dysfunction.